Cowen & Co. Downgrades Aptinyx to Market Perform
Cowen & Co. analyst Ritu Baral downgrades Aptinyx (NASDAQ:APTX) from Outperform to Market Perform.
Truist Securities Downgrades Aptinyx to Hold
Truist Securities analyst Joon Lee downgrades Aptinyx (NASDAQ:APTX) from Buy to Hold.
What 4 Analyst Ratings Have To Say About Aptinyx
Over the past 3 months, 4 analysts have published their opinion on Aptinyx (NASDAQ:APTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers
Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent…
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday’s Mid-Day Session
Gainers
Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.
Aptinyx Shares Plummet As Mid-Stage Fibromyalgia Study Missed Primary Endpoint
Aptinyx Inc. (NASDAQ: APTX) announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.
The Phase 2b clinical study was designed to evaluate the efficacy and safety of NYX-2925 in approximately 300 patients with fibromyalgia.
Aptinyx’s Chronic Pain Candidate Fails To Top Placebo In Mid-Stage Study
Aptinyx Inc (NASDAQ: APTX) has announced results from a Phase 2b study evaluating the effects of NYX-2925 in patients with fibromyalgia, characterized by muscular or musculoskeletal pain with stiffness and localized tenderness at specific points.
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers
Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.